Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25435841 | 0.86 | GPR119 (0.39) | POLBMEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL25434759 | 0.84 | STS (0.38) | POLBMEN1KMT2AESR2STS | |
| SCHEMBL26890664 | 0.82 | MEN1 (0.42) | POLBMEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL22716585 | 0.77 | NR1H2 (0.39) | POLBUSP2SMN1; SMN2ESR2STS | |
| SCHEMBL22435393 | 0.77 | NR1H2 (0.39) | POLBUSP2SMN1; SMN2ESR2ALDH1A1 | |
| SCHEMBL30793319 | 0.70 | MEN1 (0.37) | MEN1KMT2AUSP2SMN1; SMN2ESR2 | |
| SCHEMBL31035864 | 0.69 | NR1H2 (0.34) | ESR2ALDH1A1LMNAMAPTSUV39H2 | |
| SCHEMBL31510261 | 0.69 | ADORA1 (0.43) | ESR2MAPT | |
| SCHEMBL3801572 | 0.69 | THRB (0.33) | — | |
| SCHEMBL698803 | 0.68 | USP2 (0.69) | POLBMEN1KMT2AUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624052-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2025034919-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2025034883-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20250042921-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| EP-4475956-A1 | KRAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023154766-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042921-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | POLB 2999/4885MEN1 667/4885KMT2A 2875/4885 |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | POLB 2849/4885MEN1 551/4885KMT2A 2868/4885 |
| US-12624052-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | POLB 1799/4885MEN1 1379/4885KMT2A 2918/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | POLB 2849/4885MEN1 551/4885KMT2A 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.